Where Atara Biotherapeutics Stands This January: Analyst Ratings
Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.